RNANasdaqPharmaceutical PreparationsFiscal year ends December 31

Atrium Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$7.61−0.06 (-0.78%)

Close on Oct 19, 2026

Market cap: $130.18M
P/E (TTM): –
Dividend yield: –

Atrium Therapeutics, Inc. cash flow statement

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q2 2025 2025-06-30	Q1 2025 2025-03-31
Stock-Based Compensation	0.89	12	1.70	1.21
Change in Accounts Receivable	–	-15	–	0
Change in Accounts Payable	2.71	-3.59	-0.26	0.04
Change in Unearned Revenue	-3.00	-4.64	-3.85	-1.57
Operating Cash Flow	-3.93	-31	-12	-11
Capital Expenditures	-0.04	-2.10	-0.27	0
Investing Cash Flow	-192	-2.10	-0.27	0
Financing Cash Flow	0	302	12	11
Net Change in Cash	-196	268	0	0
Free Cash Flow	-3.96	-33	-12	-11

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 8.73
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 229.6%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.61
Dividend yield: –